2023
DOI: 10.3324/haematol.2023.283003
|View full text |Cite
|
Sign up to set email alerts
|

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen

Abstract: Not available.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 15 publications
0
2
0
Order By: Relevance
“…21,31,56,61 There have also been reports of prolonged viral infections, including parvovirus and norovirus, in patients receiving BCMAdirected bispecific agents. 62 Rates of grade 3/4 neutropenia appeared to be slightly higher in those treated with BCMA BsAbs versus non-BCMA BsAbs. Prolonged lymphopenia and hypogammaglobulinemia have been noted after BCMA CAR T-cell therapy.…”
Section: Toxicitymentioning
confidence: 94%
“…21,31,56,61 There have also been reports of prolonged viral infections, including parvovirus and norovirus, in patients receiving BCMAdirected bispecific agents. 62 Rates of grade 3/4 neutropenia appeared to be slightly higher in those treated with BCMA BsAbs versus non-BCMA BsAbs. Prolonged lymphopenia and hypogammaglobulinemia have been noted after BCMA CAR T-cell therapy.…”
Section: Toxicitymentioning
confidence: 94%
“…Besides hypogammaglobulinemia, persistent B cell and plasma cell suppression are associated with a high risk of viral infections that can be caused by CMV, EBV, parvovirus, HSV, BK polyomavirus, and other visceral infections [76]. Moreover, these patients show a particularly high risk of SARS-CoV-2 infections, and any grade COVID-19 occurred in 29.1% (grade 3-4: 21.2%) and 29.3% (grade 3-4: 15.4%) of patients treated with teclistamab and elranatamab, respectively [45,75].…”
Section: Peculiar Toxicities Of Belantamab Mafodotin and Bispecific A...mentioning
confidence: 99%